alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
02/07/2011 11:0: 2022675075 OFFICE OF RULEMAKING PAGE 08 

T1-856-397-9541 

FROW THE DFSK OF 

ROBERT T. HOBAN Rl-infiAMJR(g)YAHQO.COM 

January 17, 2011 

Frederick 'lUton. MD 

F'-'UTHI Aviarion Adminisiraiion 

iJrup; AlKiirmrnt Division 

AAM-800, Ko.TTn 806 

(JOO Indrpfrnririicc. Ave. S-W. 

Washmgion, DC 20501 

Dear Sir. 

\Vr, OAtalyst Aviation, TJ..C' 00 Fostcnown Road PO. Btjx 1600 Medfoid, NJ OfiO^Cy, CCTlifica^r no. H4-1'A020Y (TJOA # to be determined). Rpqut-fit lu apply for a grnju of i*^c.rn|jtion fmm Title H, Pan 120. To f>rrrnii \is, operating undrr srris!i.iv»: pwrts of the rcijulations.. To rover «,ii.ir saXcTy-rcnsidvp rmpIoyecM under one drup; and fll<:t>hnl hcsting program. 

^....fiinrrrcHi. you rs, 

Robert T. Hoban 

l?in*r.ir»r f.if Opcrarions 

tiatalysi Aviwuon, LLC. 

C ATALYST AVIATION, LLC P.O. BOX 1608 MEDFORD, NJ 08055 

CATALYSTAVIATI0N.COM 509-668-0013 
02/07/2011 11:02 2022675075 OFFICE OF RULEMAKING PAGE 09 

Professional Air Charter Services, IncDrug Abatement — AMPP Consortium 

72877 McGee Street 876-942-2144 

Kansas City, MO 64145 800-424-2144 

Fax 816-943-9464 

www.pacsdrug.com 

Januaiy 17, 2011 

Catalyst Aviation, LLC 

Attn: Robert Hoban 

PO Box 1608 

Medford, NJ 08055 

Dear Mr. Hobein: 

This letter is to advise you that Catalyst Aviation, LLC was accepted 

for meiubership by the Professional Air Charter Services, Inc., Drug 

Abatement / AMPP Consortium effective January 23, 2008. We 

appreciate your confidence in selecting us for yoior anti-drug and alcohol 

compliance services. As of today, your company and its covered 

employees are covered under the drug/alcoliol regulations of FAR Part 

120, 121, 91 , and 135 by this Consortium. You may forward this letter 

to your FSDO & POI, or to your customers, as proof of your compliance 

with the regulations. Your compliance certification will appear in Section 

A of your Operations Specifications. 

If you have any questions, problems- or comments regarding drug 

compliarice, please call anj'time, Yojaxj^Qei^tJer^hip entitles you to 

unlimited free consultation at 

Sincere] 

John Carpeni 

Program Manager
axdx_ex10135.htm

EXHIBIT 10.13.5

 

AMENDMENT 

TO

12% REVOLVING LINE OF CREDIT PROMISSOPRY NOTE DUE 2016

 

OF

 

CO-DIAGNOSTICS, INC.

 

Original Principal Amount: $75,000

Original Issuance Date: May 15, 2016 

 

Whereas, THIS AMENDMENT TO THE 12% PROMISSORY NOTE dated May 15, 2016, as amended (the “Note”) is entered into, by and between Co-Diagnostics, Inc., a Utah corporation (the “Company”) and Hamilton Mining Resources, Inc., a Utah corporation (“Holder”);

 

Now therefore, the Note is hereby amended as follows:

 

The Maturity Date shall be September 30, 2017.

 

All other terms and conditions of the Note, as amended, shall continue in full force and effect. 

 

IN WITNESS WHEREOF, the Parties have amended the Note effective as of September 14, 2016.

 

 


	
CO-DIAGNOSTICS, INC.
	
 
	
HAMILTON MINING RESOURCES, INC.

	
 
	
 
	
 

	
By: /s/ Dwight Egan 
	
 
	
By: /s/ Reed Benson

	
Dwight H. Egan 
	
 
	
 

	
President & CEO
	
 
	
Its: President
wd_EX_10_1


		
			Exhibit 10.1
		

		
			 
		

		
			WALKER & DUNLOP, INC.
		

		
			 
		

		
			NON-EXECUTIVE DIRECTOR COMPENSATION RATES
		

		
			(effective May 18, 2017)
		

		
			 
		

		
			The board of directors (the “Board”) of Walker & Dunlop, Inc. (the “Company”), adopted new compensation retainer rates for the Company’s non-employee Board members effective following the election of Board members at the Company’s May 18, 2017 annual meeting of stockholders.  
		

		
			 
		

		
			The following represents a summary of the current annual retainer rates for non-employee Board members as well as for committee member and chairperson service and the Lead Director:
		

		
			 
		

			
					
						Compensation Component

					
					
						    

					
					
						Rate

				
	
					
						Annual Retainer

					
					
						 

					
					
						$100,000 in cash and $100,000 in restricted stock (1)

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Committee Chair Cash Retainers (2)

					
					
						 

					
					
						Audit-$25,000
Compensation-$25,000
Nominating & Corporate Governance-$15,000

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Committee Member Cash Retainers

					
						 

					
					
						 

					
					
						Audit-$10,000
Compensation-$10,000
Nominating & Corporate Governance-$5,000

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Lead Director Annual Cash Retainer

					
					
						 

					
					
						$20,000

				



		
			 
		

		
			The Company also reimburses each of its Board members for his or her travel expenses incurred in connection with attendance at full Board and committee meetings.
		

		
			 
		

		


			
	
			
				 (1)
			

			
	
			
			The restricted stock vests on the one-year anniversary of the date of grant, subject to the non-executive director’s continued service on the Board.




			
	
			
				 (2)
			

			
	
			
			Committee chairpersons will receive the Committee Chair Cash Retainer in lieu of a Committee Member Cash Retainer for service on the committee they chair.
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                          11,003
<INT-BEARING-DEPOSITS>                           5,319
<FED-FUNDS-SOLD>                                   153
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     48,320
<INVESTMENTS-CARRYING>                           9,807
<INVESTMENTS-MARKET>                             9,988
<LOANS>                                        117,434
<ALLOWANCE>                                      1,746
<TOTAL-ASSETS>                                 206,347
<DEPOSITS>                                     183,454
<SHORT-TERM>                                     1,329
<LIABILITIES-OTHER>                              2,960
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         2,164
<OTHER-SE>                                       6,174
<TOTAL-LIABILITIES-AND-EQUITY>                 206,347
<INTEREST-LOAN>                                  2,911
<INTEREST-INVEST>                                  749
<INTEREST-OTHER>                                   131
<INTEREST-TOTAL>                                 3,791
<INTEREST-DEPOSIT>                               1,287
<INTEREST-EXPENSE>                                  31
<INTEREST-INCOME-NET>                            2,473
<LOAN-LOSSES>                                       62
<SECURITIES-GAINS>                                   4
<EXPENSE-OTHER>                                  3,777
<INCOME-PRETAX>                                    765
<INCOME-PRE-EXTRAORDINARY>                         765
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       545
<EPS-PRIMARY>                                     0.25
<EPS-DILUTED>                                     0.25
<YIELD-ACTUAL>                                    8.59
<LOANS-NON>                                        997
<LOANS-PAST>                                       341
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                  1,260
<ALLOWANCE-OPEN>                                 1,703
<CHARGE-OFFS>                                       49
<RECOVERIES>                                        30
<ALLOWANCE-CLOSE>                                1,746
<ALLOWANCE-DOMESTIC>                             1,746
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
##### 



Exhibit 23.1 Independent Registered Public Accounting Firms Consent We consent to the incorporation by reference in Registration Statement Nos. 33-98690 and 333-07191
of Oakley, Inc. on Form S-8 of our reports dated March 14, 2005 relating to the consolidated
financial statements and financial statement schedule of Oakley, Inc. and subsidiaries and
managements report on internal control over financial reporting, appearing in this Annual Report
on Form 10-K of Oakley, Inc. for the year ended December 31, 2004. /s/ DELOITTE & TOUCHE LLP
Costa Mesa, California
March 14, 2005
Denied; Opinion Filed August 12, 2019.

In The 

## Court of Appeals Fifth District of Texas at Dallas

No. 05
- 19
- 00916
- CV IN RE STEVEN GARCIA On Appeal from the County Court at Law No. 6

Collin County, Texas Trial Court Cause No. 006
- 02004
- 2019 

### MEMORANDUM OPINION Before Justices Myers, Molberg, and Nowell Opinion by Justice Myers Before the Court are relator’s petition for writ of mandamus and request for emergency relief, respondent’s res ponse, and relator’s reply. By his petition, relator seeks relief from the trial court’s order denying his petition for an occupational license based on a lack of “essential need.”
See T EX
. T RANSP
. C ODE A NN
. §§ 521.242, 521.244. Relator asserts the tria l court’s finding that no essential need exists for him to operate a motor vehicle was a clear abuse of discretion because he submitted all the required documentation and evidence in an ex parte hearing with no controverting evidence. He further asserts h e has no adequate remedy on appeal because of the length of time a regular appeal takes. To be entitled to mandamus relief, a relator must show both that the trial court has clearly abused its discretion and that relator has no adequate appellate remedy. In re Prudential Ins. Co. , 148 S.W.3d 124, 135

– 36 (Tex. 2004) (orig. proceeding). Based on the record before us, we– 2

–

conclude relator has not established his right to mandamus relief. We, therefore, deny relator's petition for writ of mandamus and reques t for emergency relief

.

190916F.P05 /Lana Myers/ LANA MYERS JUSTICE
[No. 16912-0-III.

Division Three.

December 11, 1997.]

#### *In the Matter of the Personal Restraint of*Jesus Gil-Sanchez, *Petitioner.*

Petition for relief from personal restraint. *Granted*by unpublished opinion per Kato, J., concurred in by Schultheis, A.C.J., and Brown, J.
Editorial Note on Part 341
Editorial Note: Nomenclature changes to part 341 appear at 69 FR 13717, Mar. 24, 2004.

§ 341.14 Antitussive active ingredients. The active ingredients of the product consist of any of the following when used within the dosage limits and in the dosage forms established for each ingredient in § 341.74(d): ( a ) *Oral antitussives.* ( 1 ) Chlophedianol hydrochloride.
( 2 ) *Codeine ingredients.* The following ingredients may be used only in combination in accordance with § 290.2 and 21 CFR 1308.15(c). ( i ) Codeine.
( ii ) Codeine phosphate.
( iii ) Codeine sulfate.
( 3 ) Dextromethorphan.
( 4 ) Dextromethorphan hydrobromide.
( 5 ) Diphenhydramine citrate.
( 6 ) Diphenhydramine hydrochloride.
( b ) *Topical antitussives.* ( 1 ) Camphor.
( 2 ) Menthol.
[52 FR 30055, Aug. 12, 1987, as amended at 59 FR 29174, June 3, 1994; 67 FR 4907, Feb. 1, 2002]
<PAGE>

                                                                     Exhibit 24


                                POWER OF ATTORNEY


                  KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby
constitutes and appoints each of Glenn P. Dickes, Barry F. Schwartz and Eric W.
Golden or any of them each acting alone, his true and lawful attorney-in-fact
and agent, with full power of substitution, for him and in his name, place and
stead, in any and all capacities, in connection with the M&F WORLDWIDE CORP.
(the "Corporation") Annual Report on Form 10-K for the year ended December 31,
2000 under the Securities Exchange Act of 1934, as amended, including, without
limiting the generality of the foregoing, to sign the Form 10-K in the name and
on behalf of the Corporation or on behalf of the undersigned as a director or
officer of the Corporation, and any amendments to the Form 10-K and any
instrument, contract, document or other writing, of or in connection with the
Form 10-K or amendments thereto, and to file the same, with all exhibits
thereto, and other documents in connection therewith, including this power of
attorney, with the Securities and Exchange Commission and any applicable
securities exchange or securities self-regulatory body, granting unto said
attorneys-in-fact and agents, each acting alone, full power and authority to do
and perform each and every act and thing requisite and necessary to be done in
and about the premises, as fully to all intents and purposes as he might or
could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, each acting alone, or his substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.

                  IN WITNESS WHEREOF, the undersigned has signed these presents
this 12th day of January 2001.



                                      /s/ Ronald O. Perelman
                                      ----------------------


                                      /s/ Jaymie A. Durnan
                                      --------------------


                                      /s/ Theo W. Folz
                                      ----------------


                                      /s/ Howard Gittis
                                      -----------------


                                      /s/ J. Eric Hanson
                                      ------------------


                                      /s/ E. Gregory Hookstratten
                                      ---------------------------


                                      /s/ Lance Liebman
                                      -----------------


                                      /s/ Paul M. Meister
                                      -------------------


                                      /s/ Bruce Slovin
                                      ----------------


                                      /s/ Stephen G. Taub
                                      -------------------
§ 251.10 Reviewing and updating registration information for Foreign Sellers. ( a ) *Expedited updates.* A Foreign Seller must update its registration information no later than 30 calendar days after: ( 1 ) Closing or being sold;
( 2 ) Changing its name or physical address; or
( 3 ) Changing the name, mailing address, telephone number, or email address of the official contact or the U.S. agent. A Foreign Seller, official contact, or U.S. agent may notify FDA about a change of information for the designated official contact or U.S. agent, but only a Foreign Seller is permitted to designate a new official contact or U.S. agent.
( b ) *Annual review and update of registration information.* A Foreign Seller must review and update all registration information required under § 251.9. ( 1 ) The first review and update must occur during the period beginning on October 1 and ending December 31 of the year of initial registration, if the initial registration occurs prior to October 1. Subsequent reviews and updates must occur annually, during the period beginning on October 1 and ending December 31 of each calendar year.
( 2 ) The updates must reflect new changes not previously required to be reported, along with a summary of the registration updates that were provided to FDA as required during the calendar year.
( 3 ) If no changes have occurred since the last registration, a Foreign Seller must certify that no changes have occurred.
[No. 38448-1-I.

Division One.

November 24, 1997.]

#### Earl Soushek, *Appellant,*v. Denise McCann, *Respondent.*

Appeal from a judgment of the Superior Court for King County, No. 93-5-03818-7, Katherine Hershey, J. Pro Tern., entered March 6, 1996. *Reversed*by unpublished opinion per Baker, C.J., concurred in by Coleman and Grosse, JJ.
38713.

#### DEMPSEY v. THE STATE.

Frankum, Judge.

This case is controlled by the following decision: “By two separate accusations the defendant was accused of two separate misdemeanors. The cases were consolidated and the defendant was tried under both accusations, and separate verdicts of guilty were returned in each case, and separate judgments thereon were rendered. A single motion for a new trial covering both cases was made by the defendant and was overruled by the court, and the defendant filed one bill of exceptions seeking a review of that judgment. *Held,*that there is no authority of law for the defendant to bring both cases to the reviewing court by one bill of exceptions, and this court has no jurisdiction to entertain the writ of error. *Dickey v. State,*101 Ga. 572 (28 S. E. 980); *Paschal v. Morgan,*19 Ga. App. 245 (91 S. E. 285); *Futch v. Mathis,*148 Ga. 558 (97 S. E. 515).” *Hornsby v. State,*44 Ga. App. 788 (163 S. E. 516).

See also *Allen v. Woods,*44 Ga. App. 430 (161 S. E. 655); *Johnson v. Lock,*35 Ga. App. 587 (134 S. E. 197); *Bridges v. State,*27 Ga. App. 767 (110 S. E. 412); *Fillingame v. State,*27 Ga. App. 764 (109 S. E. 916); *Allen v. State,*26 Ga. App. 671 (106 S. E. 796); *Chambers v. Walker,*26 Ga. App. 586 (106 S. E. 811).

*Writ of error dismissed.*

*Townsend, P. J., Carlisle and Jordan, JJ., concur.*

*355Decided February 21, 1961

Rehearing denied March 15, 1961.

*Fullbright*,<fe *Duffey, William 0. Green,*for plaintiff in error.

*Chastine Parker, Solicitor-General, Horace T. Clary, Assistant Solicitor-General,*contra.
xml version="1.0" encoding="UTF-8"?


L\_2018022EN.01004501.xml


| | | | |
| --- | --- | --- | --- |
| 26.1.2018 | EN | Official Journal of the European Union | L 22/45 |

---

Corrigendum to Commission Delegated Regulation (EU) 2018/44 of 20 October 2017 amending Delegated Regulation (EU) 2016/2374 establishing a discard plan for certain demersal fisheries in South-Western waters

(
[Official Journal of the European Union L 7 of 12 January 2018](http://publications.europa.eu/resource/oj/JOL_2018_007_R_TOC)
)

On page 4, in the Annex, Sections 3 and 6, note 1 of the tables and on page 5, Section 7, note 1 of the table:

for:

| | |
| --- | --- |
| ‘(1) | Reference period for the year 2017. For 2018 the reference period shall be 2015/2016 and for 2019 the reference period shall be 2016/2017.’, |

read:

| | |
| --- | --- |
| ‘(1) | Reference period for the year 2017. For 2018 the reference period shall be 2015/2016’. |

---
Ammoniacal Etching Plant Data TTM Technologies, Inc. North American DivisionChippewa Falls Logan San Diego Santa Ana Santa Clara Stafford 234 Cashman Drive 710 North 600 West5037 Ruffner Street 2630 S. Harbor Blvd 407 Mathew St. 4 Old Monson Road Chippewa Falls, WI 54729Logan, UT 84321 San Diego, CA 92111 Santa Ana, CA 92704 Santa Clara, CA 95050Stafford, CT 06075 Etch Supplier/Recycler Micronutrients Phibro-Tech Phibro-Tech Phibro-Tech Phibro-Tech Micronutrients Indianapolis, IN Santa Fe Springs, CASanta Fe Springs, CA Santa Fe Springs, CA Santa Fe Springs, CAIndianapolis, IN Etchant Used Ultra Etch AC-CU Fine 9 Accu Guard Plus AC-CU Fine 9 Accu Guard Plus Ultra Etch
1. Control of etcher exhaust Automatic Manual Manual Automatic Manual Automatic 2. Condenser in the exhaust pipe? Yes No Yes Yes Yes Yes 3. Frequency of pH probe cleaning/calibration Once/year 4. Acceptable pH control range 8.3-8.6 8.0-8.3 8.0-8.8 7.9-8.3 8.0-8.8 8.4=Opt 7.8 - 9.0
5. Control range for chlorides 4 - 6 M 5.0M +/- 1.0 5.8 - 7.8 moles/liter 5.3-6.7 M 5.0-6.0 oz/gal 5.0-5.8 Molar Daily (lab) When <+/- 0.1 S.U. Calibrated as needed. About every 6 months Daily
###### Editorial Note on Part 314

#### Editorial Note:

Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

#### § 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant study the drug further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome. Postmarketing studies would usually be studies already underway. When required to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence.
# United States Court of Appeals **for the Fifth Circuit**

No. 20-40032 Conference Calendar

United States of America,

Plaintiff—Appellee ,

versus

Cesar Mendoza-Hernandez,

Defendant—Appellant

.

Appeal from the United States District Court for the Southern District of Texas USDC No. 1:19-CR-625-1

Before Graves, Willett, and Duncan, Circuit Judges

. Per Curiam: *
The attorney appointed to repres ent Cesar Mendoza-Hernandez has
moved for leave to withdraw and has filed a brief in accordance with Anders v. California , 386 U.S. 738 (1967), and United States v. Flores , 632 F.3d 229 (5th Cir. 2011). Mendoza-Hernandez has filed a response. We have

* Pursuant to 5th Circuit Rule 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Circuit Rule 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED April 6, 2021
Lyle W. Cayce Clerk Case: 20-40032 Document: 00515810745 Page: 1 Date Filed: 04/06/2021No. 20-40032

2 reviewed counsel’s brief and the releva nt portions of the record reflected therein, as well as Mendoza-Hernandez’s response. We concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate review. Accordingly, counse l’s motion for leave to withdraw is
GRANTED , counsel is excused from further responsibilities herein, and the appeal is DISMISSED

. See 5th Cir. R. 42.2. Case: 20-40032 Document: 00515810745 Page: 2 Date Filed: 04/06/2021